OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Rheumatology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
No benefit from adding MTX to ustekinumab	376
Bimekizumab effective across the axSpA spectrum	319
Genome-wide mutagenesis reported in systemic sclerosis	303
The role of the patient in rheumatology	234
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	228
Rheumatic diseases on the rise	194
A role for TGFβ and EBV in MIS-C pathogenesis	191
Obexelimab reduces the risk of IgG4-RD flare	181
Biological and clinical roles of IL-18 in inflammatory diseases	180
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	179
Osteoarthritis as a systemic disease	170
Towards better management of sterile bone inflammation	167
New drug formulation reduces bone loss	159
The value of comparative efficacy studies in informing rheumatology guidelines	158
The 2022 ACR vaccination guideline: a call-to-action	155
Appraising the evolving landscape of protease inhibition in osteoarthritis	154
MIS-C: myths have been debunked, but mysteries remain	151
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	141
FOXP3 splice variant is associated with autoimmune disease	137
Urchin-like nanoparticles for miRNA therapy of OA	136
Inflammation across tissues: can shared cell biology help design smarter trials?	132
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	130
Down syndrome: insights into autoimmune mechanisms	130
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	128
Co-trimoxazole reduces mortality in anti-MDA5-DM	125

Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	124
Rheumatic diseases and metabolism: where centre and periphery meet	116
Wnt-induced IGF1 drives OA	115
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	115
A direct link between SARS-CoV-2 and bone loss	114
Calprotectin tracks tocilizumab-treated RA	110
Fumarate drives interferon release in systemic sclerosis monocytes	105
S100A4 inhibition targets fibrosis in SSc	104
Low back pain is a growing concern	99
Fibroblast TGFβ drives treatment-refractory RA	96
COPA syndrome spans multiple organs but is defined by STING in the lung	94
Author Correction: Proposals for the rheumatological use of JAK inhibitors	94
Pain in systemic lupus erythematosus: emerging insights and paradigms	93
Guiding ILD management in systemic autoimmune rheumatic diseases	92
Immune reset and immune retune: approaching cure?	92
Dysfunctional UBA1-mutated myeloid cells promote inflammation in VEXAS syndrome	86
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	81
Rheumatology in the digital health era: status quo and quo vadis?	79
Targeting the IVD clock to halt degeneration	78
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	78
Which DMARD for ICI-associated arthritis?	78
Phase III trial of telitacicept in SLE	75
A path towards personalized medicine for autoinflammatory and related diseases	73
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	71
Cell-free DNA fragmentation signatures link cancer and autoimmunity	71
Erosive cargo from synovial fibroblasts	69
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	69
ERAP1 and the return of the UPR in ankylosing spondylitis	68
CAR T cells induce drug-free SLE remission	63
Targeting ferroptosis resistance in RA fibroblast-like synoviocytes	62
Insights into IVDD pathogenesis in 2024	62
Macrophage-coated nanocarriers for gouty arthritis	60
RA risk from occupational inhalation	57
Repolarizing macrophages using antagomirs	57
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	57
Blocking CDK7 attenuates inflammatory arthritis	57
Innate lymphoid cells in rheumatoid arthritis as mediators of pathology and resolution	56
Reply to ‘Is cam morphology a cause of osteoarthritis?’	55
A critical view of WHO guidelines on management of low back pain	55
All fibroblasts are equal, but some are more equal than others	53
New developments in electronic health record analysis	52
Two sides of management recommendations for psoriatic arthritis	51
TASL has a key role in SLE	50
A leading role for interferon as a treatment target in Sjögren syndrome	50
Platelets as drivers of immunothrombosis in rheumatic diseases	48
Fibroblast heterogeneity in 2025	46
Profiling joint tissues at single-cell resolution: advances and insights	46
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	45
New refinements aim to optimize articular cartilage tissue engineering	45
AhR promotes suppressor cell function in Sjögren syndrome	44

Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	44
Unravelling the cellular mechanisms of VEXAS syndrome	44
Fertility, pregnancy and lactation in women with systemic lupus erythematosus	43
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	43
Metabolic masqueraders of paediatric and adult rheumatic diseases	43
Piezo1 induces new bone formation in AS	40
Author Correction: Glycobiology of rheumatic diseases	39
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	39
Treg cell-inducing nanoparticles show promise for treating OA	38
Pathogenic antibodies target stromal antigens in RA	37
APOE in fat pad and synovium contributes to knee OA	36
CXCL5 effective in mouse model of SLE	36
Rethinking early-stage knee osteoarthritis beyond radiography	35
Progress made and the road ahead for cancer screening in myositis	35
Sex- and gender-based personalized medicine in rheumatology	35
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	35
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies	35
BiTE therapy for rheumatic diseases	34
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	34
Location-specific treatment of chronic inflammatory joint disease	34
FABP4 exacerbates RA	32
STING-driven necroptosis linked to autoinflammatory disease	32
Senotherapeutics suppress disc degeneration	31
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	31
Shifting the SLE management paradigm: challenges and implications	30
Critical appraisal of serum urate targets in the management of gout	30
Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis	29
Post-transcriptional checkpoints in autoimmunity	29
In vivo CAR-T cell engineering in refractory SLE	28
Multi-omics reveals distinct MPA subtypes	27
Parathyroid hormone receptor agonists in the management of osteoporosis	27
Adropin inhibits fibrosis in SSc	26
Engineered sialylated IgG1 Fc as a dose-sparing alternative to IVIG	26
COVID-19 linked to rise in anti-MDA5 autoimmunity	26
Notch signalling mediates OA pain in mice	26
Busting the myth of methotrexate chronic hepatotoxicity	25
Complement therapeutics are coming of age in rheumatology	25
State-of-the-art evidence in the treatment of systemic sclerosis	25
The potential contribution of in silico studies to improved treatment of osteoarthritis	24
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	24
Citrulline immunity in RA: CD8+ T cells enter the scene	24
Identifying fibromyalgia phenotypes based on psychological symptom burden	22
What rheumatology can learn from oncology: a patient’s perspective	22
Treatment of non-systemic juvenile idiopathic arthritis	21
The immune health metric as an indicator of health and disease	20
Advances in understanding preclinical rheumatoid arthritis and prospects for prevention	20
Primary care rheumatology: towards sustainable development in health	20
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	20
Undiagnosed axSpA is prevalent in IBD	20
The PU.1– IL-9 axis in TH9 cells promotes RA	20
Update on the pathophysiology and treatment of primary Sjögren syndrome	20
Glycosylation switch in synovial fibroblasts promotes ECM degradation	20
Bone-modifying drugs slow OA progression	20
Combination therapy for Behçet uveitis	19
Shedding light onto the immunometabolic effects of glucocorticoids	19
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	18
UNC93B1 variants promote SLE via TLR activation	18
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	18
SIX1 and PAI-1 emerge as therapeutic targets in systemic sclerosis	18
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	17
More than a leaky gut: how gut priming shapes arthritis	17
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	16
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	16
Reversal of inflammatory priming prevents arthritic flares	16
Disease stratification in GCA and PMR: state of the art and future perspectives	15
Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases	15
Global epidemiology of spondyloarthritis	15
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	15
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	15
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	14
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	14
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	14
Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases	14
Evidence-Based Guideline for the management of osteoporosis in men	13
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	13
PPM1A: TGFβ regulator and therapeutic target in OA	13